TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
复制标题
TP53 Arg72 作为 CHOP 治疗的中国弥漫性大 B 细胞淋巴瘤患者的有利预后因素
DOI：
10.1186/s12885-017-3760-0
复制
发表时间：
2017-11-10
期刊：
影响因子：
3.8
通讯作者：
Zhu J
中科院分区：
文献类型：
--
作者：
Liu Y;Wang X;Ding N;Mi L;Ping L;Jin X;Li J;Xie Y;Ying Z;Liu W;Zhang C;Deng L;Song Y;Zhu J
TP 53 Arg 72 Pro（SNP rs 1042522）与非霍奇金淋巴瘤（NHL）的风险相关。弥漫性大B细胞淋巴瘤（DLBCL）是NHL最常见的亚型。然而，该SNP与亚洲人DLBCL预后之间的关系尚不清楚。对425例中国DLBCL患者进行TP 53 Arg 72 Pro基因分型。289例患者接受R-CHOP治疗，136例患者接受CHOP或CHOP类作为一线治疗方案。396例患者可评估疗效。TP 53第72位密码子Arg/Arg和Arg/Pro的患者完全缓解率（61%）高于Pro/Pro的患者（44%）（P = 0.007）。在接受CHOP或CHOP样治疗的亚组中，Arg/Arg和Arg/Pro组的5年总生存率（OS）高于Pro/Pro组（68.8% vs. 23.2%，P = 0.001）。多因素考克斯回归分析显示TP 53 Arg 72是该组的有利预后因素。然而，利妥昔单抗与CHOP联合治疗使Pro/Pro患者的5年OS率显著增加至63%。该研究显示TP 53 Arg 72是接受CHOP或CHOP样一线治疗的中国DLBCL患者的有利预后因素。
TP53 Arg72Pro (SNP rs1042522) is associated with risk of non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. However, the relationship between this SNP and prognosis of DLBCL in Asians is unknown. Genotyping of TP53 Arg72Pro was done in 425 Chinese DLBCL patients. Two hundred and eighty-nine patients were treated with R-CHOP, and 136 patients received CHOP or CHOP-like as frontline regimen. Three hundred and ninety-six patients were assessable for the efficacy. Patients with Arg/Arg and Arg/Pro at codon 72 of TP53 had a higher complete response rate (61% vs. 44%, P = 0.007) than those with Pro/Pro. In the subgroup treated with CHOP or CHOP-like therapy, patients with Arg/Arg and Arg/Pro showed a higher 5-year overall survival (OS) rate than those with Pro/Pro (68.8% vs. 23.2%, P = 0.001). Multivariate Cox regression analysis revealed TP53 Arg72 as a favorable prognostic factor in this group. However, the combination of rituximab with CHOP significantly increased the 5-year OS rate of patients with Pro/Pro to 63%. This study revealed TP53 Arg72 as a favorable prognostic factor for Chinese DLBCL patients treated with CHOP or CHOP-like as frontline therapy.
登录
查看更多内容
影响因子：
30.8
作者：
Dumont, P;Leu, JIJ;Murphy, M
通讯作者：
Murphy, M
影响因子：
51.1
作者：
Pfreundschuh, Michael;Schubert, Joerg;Loeffler, Markus
通讯作者：
Loeffler, Markus
影响因子：
2.3
作者：
Weich, Natalia;Ferri, Cristian;Fundia, Ariela
通讯作者：
Fundia, Ariela
影响因子：
51.1
作者：
Pfreundschuh, Michael;Trumper, Lorenz;Loeffler, Markus
通讯作者：
Loeffler, Markus
影响因子：
28.5
作者：
Suresh T;Lee LX;Joshi J;Barta SK
通讯作者：
Barta SK